Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Healthy outlook at Drew

Tom Stevenson
Tuesday 18 May 1993 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

DREW Scientific joins the procession of high-tech flotations next Monday when dealings start in its shares. Valued at pounds 25m by a 105p institutional placing, the medical products company looks likely to continue the trend of first-day premiums, with the shares oversubscribed.

Drew makes analytical equipment to measure haemoglobin levels in blood samples as part of the diagnosis of diabetes. About 2 per cent of the world's population suffers from the disease. The main product, Glycomat, automatically tests up to 100 blood samples. A smaller version will be launched this year.

Drew made a first operating profit in the year to March of pounds 20,000 but the company says sales are accelerating, mainly thanks to its foray into the US. Last-quarter sales of pounds 900,000 represented more than half the total for the year.

RPC Group, the plastic packaging group, is joining the market via a pounds 35m placing and intermediaries offer, valuing it at pounds 75m. Two-thirds of the 28 million shares being issued are placed with institutional investors and the balance are being offered at 125p each. Dealings start on 28 May.

The company made pounds 6.8m before tax in the year to 31 March.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in